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Instigated at the beginning of the 20th century, modern
transplantation has triggered an unprecedented era for med-
ical therapeutics. Indeed, the feasibility to successfully trans-
plant cells, tissues, or organs derived from an allogeneic
donor has opened the way to novel approaches to rescue
and prolong the life of patients with end-stage organ failure.
However nowadays, due to an increasing gap between the
demand for organs and the limited number of human
donors, allogeneic transplantation is, unfortunately, a thera-
peutic option that is not always available to those in need.
In the dramatic scenario of human donor shortage and
increasing transplantation waiting lists, transplanting organs
from other species such as the pig into man, a condition
known as xenotransplantation, might represent an appealing
therapeutic solution for a larger population of patients
aﬀected by organ failure. Despite the well-established sim-
ilarities with regards to some aspects of anatomy and
physiology between pigs and humans, transplanting pig
tissues and organs into man is known to elicit an aggres-
sive immune reaction that commonly results in premature
failure of the graft.
Breakthroughs in the understanding of the mechanisms
underlying xenograft rejection, that include advancements
in glycoimmunology, proteomics, and molecular signaling,
have enabled the development of novel modalities to pre-
vent or delay the development of antixenograft immune
responses. In fact, innovative strategies have been devised to
modulate the recipient’s immune response to xenografts, to
reduce the immunogenic power of transplanted cells, tissues,
and organs, or to create a physical barrier between the
human blood and the xenograft. However, the route to the
clinical application of xenotransplantation still presents
many hurdles that will need to be overcome before reaching
its ambitious therapeutic goal.
In this special issue, we aim to oﬀer an overview of the
state of the art of xenotransplantation with reference to the
continuous innovation and potential issues in this challeng-
ing medical ﬁeld. In particular, G. P. Yung and colleagues
review the role of human natural killer (NK) cells in the path-
ophysiological mechanisms leading to xenograft rejection (in
The Role of NK Cells in Pig-to-Human Xenotransplantation).
In this context, the authors accurately describe speciﬁc
molecular strategies to overcome the human NK response
directed against porcine endothelial cells. As previously evi-
denced for NK immune responses, costimulatory molecules
represent a key target of intervention to optimize immuno-
modulation in xenotransplantation. In the review by K. P.
Samy et al. (in The Role of Costimulation Blockade in Solid
Organ and Islet Xenotransplantation), the central role of
such approaches is illustrated in enabling xenotransplanta-
tion of solid organs, as kidney, heart, and liver, as well as
of islets. Speciﬁcally, advancements in terms of survival
achieved in preclinical models with the introduction of
monoclonal antibodies against CD154, CD40, and CTLA-4
are discussed. E. Montanari et al. cover another strategy that
might possibly improve xenograft durability. This approach
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is represented by the protection oﬀered to hepatocytes by
cotransplantation with multipotent mesenchymal stem cells
(MSCs) (in Beneﬁcial Eﬀects of Human Mesenchymal
Stromal Cells on Porcine Hepatocyte Viability and Albumin
Secretion). In fact, alginate-encapsulated hepatocytes dem-
onstrated higher viability and albumin secretion upon cocul-
ture with MSCs thanks to the paracrine eﬀect of their
secreted cytokines CCL2, CXCL12, and macrophage migra-
tion inhibitory factor (MIF). Such original results are of
great interest for the success of cell transplantation in the
setting of acute liver failure and once again, conﬁrm the
powerful immunomodulatory and protective abilities of
MSCs when applied as ancillary therapies or alone.
Besides immune response, other pitfalls in the clinical
application of xenotransplantation could be represented by
inappropriate organ function and growth adaptation, also
developed in the long term. J. A. Shah and colleagues analyze
the possible causes of post-transplant proteinuria in preclin-
ical renal xenotransplantation and summarize the preventive
strategies that are currently being tested/applied (in Potential
Pathways behind Proteinuria as well as Factors Related to
Growth Discrepancies following Pig-to-Kidney Xenotrans-
plantation). In addition, they highlight the importance of
organ size match since discrepancies may ultimately be a
cause of xenograft failure. Lastly, in their review, C. G. A.
McGregor and G. W. Byrne examine the current barriers
hindering access of heart xenotransplantation in the clinical
arena (in Porcine to Human Heart Transplantation: Is Clini-
cal Application Now Appropriate?). Following an accurate
description of the technological progress that has enabled
the current preclinical results in nonhuman models, the
remaining key preclinical studies indispensable to ensure
the eﬃcacy and safety of clinical cardiac xenotransplantation
are discussed.
In this continuous cross talk between fundamental
and applied research, progress is very encouraging and
clinical translation of novel therapeutic solutions based on
the use of animal-derived cells, tissue, or organs appears
increasingly closer.
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